Results 171 to 180 of about 674,033 (286)

Rapid Documentation of Possible Semen Stains for Forensic DNA Profiling. [PDF]

Genes (Basel)
Thong Z, Wee APJ, Heng B, Syn CKC.
europepmc   +1 more source

Allele frequency and proportion defined by circulating tumor DNA profiling predict tyrosine kinase inhibitors' therapeutic outcomes for non-small cell lung cancer. [PDF]

J Cancer Res Clin Oncol, 2023
Song J, Bai L, Zhai J, Xin Z, You L, Zhou Y, Zhou J, Ying B.   +7 more
europepmc   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Comprehensive DNA profiling strategy for patient-derived xenograft model authentication in the J-PDX library. [PDF]

Sci Rep
Yoshino T, Yagishita S, Takahashi M, Ushie C, Takahashi A, Yatabe Y, Kohsaka S, Ueno T, Ono H, Shiraishi K, Hamada A.   +10 more
europepmc   +1 more source

The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment. [PDF]

Transl Lung Cancer Res, 2021
Ma S, Shi M, Chen X, Wang Y, Yang Z, Lizaso A, Li M, Li H, Zhang L, Mao X, Xu X, Song Y.   +11 more
europepmc   +1 more source

DNA profiling in India [PDF]

Nature Methods, 2015
openaire   +2 more sources

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. [PDF]

Cancer Cell Int, 2021
Fernandes MGO, Cruz-Martins N, Machado JC, Costa JL, Hespanhol V.   +4 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Improved circulating tumor DNA profiling by simultaneous extraction of DNA methylation and copy number information from methylated DNA sequencing data. [PDF]

NPJ Precis Oncol
Hazelaar DM, Boers RG, Boers JB, de Weerd V, Helmijr J, Phm Jansen M, Mw Verheul H, Verhoef C, Gribnau J, Martens JW, Makrodimitris S, Wilting SM.   +11 more
europepmc   +1 more source